Page 1

28/10/21 ASX Release VISION EMVI EMVision Medical Devices Ltd ACN 620 388 230 Level 10 , 12 Creek Street , Brisbane Qld 4000 02 8667 5337 contact@emvision.com.au APPENDIX 4C - 30 SEPTEMBER 2021 QUARTERLY ACTIVITIES & CASHFLOW REPORT Highlights : • • • • An important milestone for the Company was reached with the fabrication and assembly of the Company's alpha unit of its 1st Gen portable brain scanner intended for commercialisation . Testing of the 1st Gen units has been initiated . EMVision and The Australian Stroke Alliance Limited ( " ASA ” ) signed a binding Project Agreement enabling EMVision to begin accessing $ 8m in non - dilutive staged cash funding . After a rigorous peer - review process , EMVision was pleased to have patient case study images and an introduction to EMVision's novel portable brain scanner technology published in the medical journal Frontiers of Neurology . $ 8.054 million of cash reserves as at 30 September 2021 , first $ 600k milestone grant due under ASA Project Agreement received subsequent to quarter end . R & D Tax Incentive claim for FY21 to be lodged shortly . EMVision Medical Devices Limited ( ASX : EMV ) ( “ EMVision ” or the “ Company ” ) is pleased to lodge the following update and attached Appendix 4C Quarterly Cashflow Report for the 3 - month period ended 30 September 2021 . In partnership with The University of Queensland ( UQ ) , EMVision is developing and commercialising medical imaging diagnostics for various disease states and medical emergencies . The Company's primary focus is a portable , cost effective , non - invasive brain scanner to monitor and help with the diagnosis of brain injuries and stroke by creating rapid images of the brain at the point - of - care . Key activities undertaken during the quarter are outlined below : 1st Gen successfully manufactured , enrolment of 20 additional patients in pilot trial completed During the quarter , EMVision was pleased to reach an important milestone for the Company with the fabrication and assembly of the Company's alpha unit of its 1st Gen portable brain scanner intended for commercialisation . Testing of the 1st Gen units has been initiated and will include functional , reliability , integration ( software and hardware ) , preliminary safety , performance , compliance and other tests intended to meet international regulatory standards . Product suitability for manufacturability , assembly , shipment ( environmental impact ) , use , service and repair will also be assessed . Tests initiated include internal formative usability studies ( including consumables and accessories ) , headset thermal tests , electrical tests ( integration of the customized VNA ( pre - production version ) in the headset ) , calibration procedure checks and performance evaluation of control mechanisms . Furthermore , qualification of the manufacturing methods and materials for critical parts and processes has also been initiated . The progress of testing has been pleasing in preparation for the Company's planned expanded clinical studies . www.emvision.com.au 1